Since March 2020, Uganda has been battling COVID-19 which has created fear, claimed over 300 lives and also crippled day to day business.
On President Museveni’s orders, the Presidential Scientific Initiative on Epidemics (PRESIDE) platform was launched to help in developing solutions/ products and tools to respond to epidemics (covid19 pandemic and beyond) in conjunction with, the natural chemotherapeutic society in Uganda, the scientific society.
The team has developed the first Ugandan natural chemotherapeutic covid19 treatment product which is to go through an international level clinical trial process.
The product has been proved safe and the trial is basically to prove its efficacy against COVID 19. The success of the clinical trials will give hope to the country by reducing the number of patients who are succumbing to the disease on a daily and also curb the spread of the virus in the community at a time when the country has just concluded its general elections.
Professor Moses Joloba, the Dean School of Biomedical Sciences Makerere University College of Health sciences and one of the Scientists involved in product development said, “It is one thing to be a laboratory researcher and another to be a product manufacturer. The launch of the clinical trial is a big milestone for the natural chemotherapy industry and giant step for Ugandan Scientists.”
Today is the convergence point between the conventionalmedical fraternity and the natural chemotherapy, which is going to revolutionize the pharmaceutical industry and the private sector in the country.
The results of the clinical trial will be internationally accepted because a robust team of clinical trial experts has been instituted including Ugandan scientists based at Natural Chemotherapeutics Research Institute, Ministry of Health in collaboration with those in Makerere University School of Medicine, Makerere University Lung Institute, Makerere University School of Public Health, Mulago Hospital and Presidential Scientific Initiative on Epidemics (PRESIDE).
Patients have been urged to welcome the clinical trial and willingly participate in the process by contacting the Clinical Coordinator on +256-782-404431. The product has been proved safe and the trial is basically to prove its efficacy against COVID 19.